Systemic sclerosis

Y Allanore, R Simms, O Distler… - Nature reviews Disease …, 2015 - nature.com
Systemic sclerosis is a complex autoimmune disease characterized by a chronic and
frequently progressive course and by extensive patient-to-patient variability. Like other …

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative

…, S Sierakowski, RM Silver, RW Simms… - Arthritis & …, 2013 - Wiley Online Library
Objective The 1980 American College of Rheumatology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

[HTML][HTML] Cyclophosphamide versus placebo in scleroderma lung disease

…, A Theodore, R Simms, R Wise… - … England Journal of …, 2006 - Mass Medical Soc
Background We conducted a double-blind, randomized, placebo-controlled trial to determine
the effects of oral cyclophosphamide on lung function and health-related symptoms in …

Digital ulcers in systemic sclerosis: prevention by treatment with bosentan, an oral endothelin receptor antagonist

…, A Herrick, PA Merkel, R Simms… - Arthritis & …, 2004 - Wiley Online Library
Objective Recurrent digital ulcers are a manifestation of vascular disease in patients with
systemic sclerosis (SSc; scleroderma) and lead to pain, impaired function, and tissue loss. We …

Recent developments in infrared fiber optics∗

NS Kapany, RJ Simms - Infrared Physics, 1965 - Elsevier
This paper reports more recent work in the area of infrared fiber optics, concentrating on the
fabrication and optical evaluation of fiber optics components from the arsenic-sulphur …

The role of vitamin D in corticosteroid‐induced osteoporosis: a meta‐analytic approach

S Amin, MP LaValley, RW Simms… - Arthritis & Rheumatism …, 1999 - Wiley Online Library
Objective To determine if vitamin D is more effective than no therapy or calcium alone in the
management of corticosteroid‐induced osteoporosis, and to determine how vitamin D …

Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group …

…, R Meehan, A Theodore, R Simms… - The lancet Respiratory …, 2016 - thelancet.com
Background 12 months of oral cyclophosphamide has been shown to alter the progression
of scleroderma-related interstitial lung disease when compared with placebo. However, …

Tocilizumab in systemic sclerosis: a randomised, double-blind, placebo-controlled, phase 3 trial

…, A Nami, S Pang, G Rios, R Simms… - The Lancet …, 2020 - thelancet.com
Background A phase 2 trial of tocilizumab showed preliminary evidence of efficacy in systemic
sclerosis. We assessed skin fibrosis and systemic sclerosis-associated interstitial lung …

2013 classification criteria for systemic sclerosis: an American College of Rheumatology/European League against Rheumatism collaborative initiative

…, PA Merkel, S Sierakowski, RM Silver, RW Simms… - 2013 - deepblue.lib.umich.edu
Objective. The 1980 American College of Rheuma-tology (ACR) classification criteria for
systemic sclerosis (SSc) lack sensitivity for early SSc and limited cutaneous SSc. The present …

Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease

…, A Theodore, R Simms, R Wise… - American journal of …, 2007 - atsjournals.org
Rationale: The Scleroderma Lung Study enrolled 158 patients with scleroderma-related
interstitial lung disease in a placebo-controlled trial of oral cyclophosphamide (CYC). Although …